Compugen Ltd. (NASDAQ:CGEN) – Stock analysts at Jefferies Group dropped their FY2018 earnings per share (EPS) estimates for Compugen in a note issued to investors on Wednesday, Zacks Investment Research reports. Jefferies Group analyst P. Welford now forecasts that the biotechnology company will post earnings of ($0.85) per share for the year, down from their prior forecast of ($0.82). Jefferies Group also issued estimates for Compugen’s FY2019 earnings at ($1.02) EPS, FY2020 earnings at ($1.22) EPS and FY2021 earnings at ($1.40) EPS.
A number of other equities research analysts have also commented on the company. Zacks Investment Research lowered Compugen from a “hold” rating to a “sell” rating in a research report on Wednesday, November 29th. ValuEngine lowered Compugen from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st.
Shares of Compugen (NASDAQ CGEN) remained flat at $$4.30 during trading hours on Monday. The company had a trading volume of 187,358 shares, compared to its average volume of 275,917. The company has a market capitalization of $210.30, a price-to-earnings ratio of -5.94 and a beta of 0.30. Compugen has a 52-week low of $2.25 and a 52-week high of $5.40.
Compugen (NASDAQ:CGEN) last issued its earnings results on Wednesday, February 21st. The biotechnology company reported ($0.18) earnings per share for the quarter.
Institutional investors have recently made changes to their positions in the company. Paloma Partners Management Co purchased a new stake in shares of Compugen during the 4th quarter valued at $105,000. Virtu Financial LLC purchased a new stake in shares of Compugen during the 4th quarter valued at $162,000. Jane Street Group LLC purchased a new stake in shares of Compugen during the 4th quarter valued at $192,000. Benjamin F. Edwards & Company Inc. increased its position in shares of Compugen by 35.4% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 85,300 shares of the biotechnology company’s stock valued at $213,000 after purchasing an additional 22,305 shares during the last quarter. Finally, Anson Funds Management LP purchased a new stake in shares of Compugen during the 4th quarter valued at $281,000. 23.41% of the stock is owned by hedge funds and other institutional investors.
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.